














Single Pharmaceutical-Based Strategy Aims to Solve Neurological and Psychiatric Disorders
Published in Health and Fitness on Wednesday, October 19th 2011 at 4:48 GMT by Market Wire

October 19, 2011 07:36 ET
Single Pharmaceutical-Based Strategy Aims to Solve Neurological and Psychiatric Disorders
LOS ANGELES, CA--(Marketwire - Oct 19, 2011) - One pharmaceutical company, Cortex Pharmaceuticals (
An exclusive Q&A with Mark Varney, President and CEO of Cortex Pharmaceuticals, reveals details about research by Cortex and its collaborators, including how Professors Gary Lynch and Christine Gall from the University of California, Irvine, have demonstrated that certain compounds may restore function to previously damaged areas of the brain.
The exclusive report is now available at:
In addition, investors may access BioMedReports' [ new complete FDA Calendar and database of clinical trials and world-wide regulatory decisions ] for use as a tool in more profitable trading by visiting:
[ http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html ]
News developments and live healthcare sector updates are available constantly via twitter at: [ http://twitter.com/BioMedReports ]
About BioMedReports.Com
BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com